GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Cyclically Adjusted FCF per Share

Jafron Biomedical Co (SZSE:300529) Cyclically Adjusted FCF per Share : ¥0.53 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Jafron Biomedical Co's adjusted free cash flow per share for the three months ended in Mar. 2024 was ¥0.505. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥0.53 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-09), Jafron Biomedical Co's current stock price is ¥27.49. Jafron Biomedical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was ¥0.53. Jafron Biomedical Co's Cyclically Adjusted Price-to-FCF of today is 51.87.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Jafron Biomedical Co was 55.28. The lowest was 34.69. And the median was 44.96.


Jafron Biomedical Co Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Jafron Biomedical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Cyclically Adjusted FCF per Share Chart

Jafron Biomedical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.49

Jafron Biomedical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.49 0.53

Competitive Comparison of Jafron Biomedical Co's Cyclically Adjusted FCF per Share

For the Medical Devices subindustry, Jafron Biomedical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jafron Biomedical Co's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jafron Biomedical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Jafron Biomedical Co's Cyclically Adjusted Price-to-FCF falls into.



Jafron Biomedical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jafron Biomedical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.505/115.2271*115.2271
=0.505

Current CPI (Mar. 2024) = 115.2271.

Jafron Biomedical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 95.237 0.000
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201503 0.030 99.900 0.035
201506 0.023 99.500 0.027
201509 0.046 100.500 0.053
201512 0.105 100.600 0.120
201603 0.022 102.200 0.025
201606 0.031 101.400 0.035
201609 0.044 102.400 0.050
201612 0.099 102.600 0.111
201703 0.057 103.200 0.064
201706 0.074 103.100 0.083
201709 -0.012 104.100 -0.013
201712 0.043 104.500 0.047
201803 0.057 105.300 0.062
201806 0.113 104.900 0.124
201809 -0.056 106.600 -0.061
201812 0.147 106.500 0.159
201903 0.062 107.700 0.066
201906 0.139 107.700 0.149
201909 0.051 109.800 0.054
201912 0.198 111.200 0.205
202003 0.133 112.300 0.136
202006 0.154 110.400 0.161
202009 0.063 111.700 0.065
202012 0.386 111.500 0.399
202103 0.074 112.662 0.076
202106 0.180 111.769 0.186
202109 0.032 112.215 0.033
202112 0.590 113.108 0.601
202203 -0.022 114.335 -0.022
202206 0.223 114.558 0.224
202209 -0.068 115.339 -0.068
202212 0.378 115.116 0.378
202303 0.252 115.116 0.252
202306 0.195 114.558 0.196
202309 0.154 115.339 0.154
202312 0.232 114.781 0.233
202403 0.505 115.227 0.505

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Jafron Biomedical Co  (SZSE:300529) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Jafron Biomedical Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=27.49/0.53
=51.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Jafron Biomedical Co was 55.28. The lowest was 34.69. And the median was 44.96.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Jafron Biomedical Co Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Jafron Biomedical Co (SZSE:300529) Business Description

Traded in Other Exchanges
N/A
Address
No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085
Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.
Executives
Li Feng Director
He Xiao Lian Executives
Dong Fan Directors, Directors, and Executives
Ceng Kai Directors, executives
Tang Xian Min Directors, executives
Zhang Ming Yuan Secretary Dong
Fang Li Hua Supervisors
Zhang Guang Hai Directors, executives
Li De Zhi Executives
Lu Shao Zhang Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines